Formycon Past Earnings Performance

Past criteria checks 0/6

Formycon has been growing earnings at an average annual rate of 16.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 4.7% per year.

Key information

16.3%

Earnings growth rate

16.1%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate4.7%
Return on equity-9.9%
Net Margin-61.5%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Formycon makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:FYBD Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2369-421314
31 Mar 2356-31316
31 Dec 2242361317
30 Sep 2238571115
30 Jun 2234771013
31 Mar 223532815
31 Dec 2137-13717
30 Sep 2137-15423
30 Jun 2138-15812
31 Mar 2136-1196
31 Dec 2034-769
30 Sep 2033-4100
30 Jun 2032-3100
31 Mar 2033-3100
31 Dec 1933-290
30 Sep 1934-290
30 Jun 1936-180
31 Mar 1939380
31 Dec 1843780
30 Sep 1844870
30 Jun 1845970
31 Mar 1837470
31 Dec 1729-260
30 Sep 1724-460
30 Jun 1719-660
31 Mar 1719-550
31 Dec 1620-450
30 Sep 1618-350
30 Jun 1616-250
31 Mar 1616-140
31 Dec 1517140
30 Sep 1519040
30 Jun 1522030
31 Mar 1517030
31 Dec 1413130
31 Dec 130-830

Quality Earnings: FYBD is currently unprofitable.

Growing Profit Margin: FYBD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FYBD is unprofitable, but has reduced losses over the past 5 years at a rate of 16.3% per year.

Accelerating Growth: Unable to compare FYBD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FYBD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).


Return on Equity

High ROE: FYBD has a negative Return on Equity (-9.88%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/27 14:20
End of Day Share Price 2023/06/30 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Formycon AG is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard OrgonasBerenberg
Benjamin ThielmannBerenberg
Simon ScholesFirst Berlin Equity Research GmbH